Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Biochemical Potency on JAK1, JAK2, JAK3 and Tyk2 from US Patent US20240209001: "HETEROCYCLIC DERIVATIVES AS JANUS KINASE INHIBITORS"
Assay data:10 Active, 10 Activity ≤ 1 µM, 10 Tested
SummaryRelated BioAssays by Target
Inhibition Tests on JAK-1, JAK-2 and JAK-3 Kinases from US Patent US11993603: "Preparation for 6-amino-1H-pyrazolo[3,4-d]pyrimidine-based JAK kinase inhibitor and application thereof"
Assay data:28 Active, 11 Activity ≤ 1 nM, 28 Activity ≤ 1 µM, 28 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMRelated BioAssays by Target
In Vitro JAK Kinase Assay from US Patent US11992490: "Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP)"
Assay data:26 Active, 26 Activity ≤ 1 µM, 26 Tested
Biochemical Potency JAK1 Assay from US Patent US20240166651: "HETEROCYCLIC DERIVATIVES AS JANUS KINASE INHIBITORS"
Assay data:10 Active, 8 Activity ≤ 1 µM, 10 Tested
In Vitro JAK Kinase Assay from US Patent US11957661: "JAK1 pathway inhibitors for the treatment of vitiligo"
Biochemical Kinase Assay Protocol (JAK) from US Patent US20240132525: "BORON CONTAINING PYRIMIDINE COMPOUNDS, COMPOSITIONS COMPRISING THEM, METHODS AND USES THEREOF"
Assay data:90 Active, 39 Activity ≤ 1 nM, 91 Activity ≤ 1 µM, 91 Tested
ADP-Glo Kinase Assay from US Patent US20240109890: "BRIDGED HETEROCYCLYL-SUBSTITUTED PYRIMIDINE COMPOUNDS, PREPARATION METHOD AND MEDICAL USE THEREOF"
Assay data:6 Active, 6 Activity ≤ 1 µM, 6 Tested
Biochemical JAK Kinase Assays from US Patent US20240092758: "IMIDAZOLO INDAZOLE COMPOUNDS AS JAK INHIBITORS"
Assay data:392 Active, 381 Activity ≤ 1 nM, 392 Activity ≤ 1 µM, 392 Tested
In Vitro Test of Activities of Jak1, Jak2, Jak3, Tyk2 Kinases from US Patent US11919896: "[1,2,4]triazolo[1,5-a]pyridine compound as JAK inhibitor and use thereof"
Assay data:34 Active, 34 Activity ≤ 1 µM, 34 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMRelated BioAssays by DepositorRelated BioAssays by Target
In Vitro JAK Kinase Assay from US Patent US11918581: "Combination therapy comprising JAK pathway inhibitor and rock inhibitor"
In Vitro JAK Kinase Assay from US Patent US20240058343: "TREATMENT OF URTICARIA USING JAK INHIBITORS"
NanoBRET assay (JAK1, SGC Frankfurt)
Assay data:2 Tested
Inhibition of JAK1 (unknown origin) at 1 uM relative to control
Assay data:3 Tested
SummaryPubMed CitationRelated BioAssays by Target
Assay data:1 Tested
Inhibition of JAK1/3 dependent IL-2 stimulated STAT5 phosphorylation in CD3-positive T cells (unknown origin)
Assay data:1 Active, 1 Activity ≤ 1 µM, 1 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMPubMed CitationRelated BioAssays by Target
Inhibition of JAK1 JH2 (unknown origin) at 10 uM by DiscoverX KINOMEscan relative to control
Inhibition of JAK (unknown origin)
Assay data:5 Active, 5 Activity ≤ 1 nM, 5 Activity ≤ 1 µM, 5 Tested
Inhibition of JAK1 (unknown origin) by Ambit kinase assay
Inhibition of JAK1/JAK3 in human M07E cells assessed as reduction of IL-15 stimulated STAT phosphorylation preincubated for 30 mins followed by IL-15 stimulation for 15 mins by flow cytometry method
Assay data:4 Active, 4 Activity ≤ 1 µM, 5 Tested
Inhibition of GST-fused JAK1 (866 to 1154 residues) (unknown origin) using FITC-AhxKKSRGDYMTMQIG-NH2 peptide as substrate incubated for 60 mins in presence of ATP by Janus kinase assay
Assay data:5 Active, 4 Activity ≤ 1 µM, 5 Tested
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on